These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
Argenx has announced the first person has been dosed in its phase 3 trial to test efgartigimod in individuals with the autoimmune condition, myasthenia gravis.
Alexion Pharmaceuticals has announced the U.S Food and Drug Administration have approved their drug for individuals with generalised myasthenia gravis.
Alexion Pharmaceuticals has released interim results from their extension trial of the original REGAIN phase 3 study.
We’re pleased to share the news that the EMA CHMP has given a positive opinion on eculizumab as a treatment for people with refractory generalised myasthenia gravis.
Handouts and slides from the Myasthenia Gravis Foundation of America’s 2017 national conference are available on its website. These might be a useful resource for people with MG.
Alexion Pharmaceuticals has applied to the European Medicines Agency (EMA) for a licence to market eculizumab (Soliris) as a treatment for refractory generalised myasthenia gravis.
A recent study in the New England Journal of Medicine has found that surgical removal of the thymus gland (thymectomy) provides significant benefit to people with myasthenia gravis
Alexion Pharmaceuticals has recently completed its phase 3 REGAIN trial testing eculizumab in people with refractory generalised myasthenia gravis, a rare form of myasthenia gravis
Researchers have identified a protein that plays a role in the development of symptoms in an animal model of myasthenia gravis and may represent a target for future therapeutics.
Prof John Weinman and researcher Chris Graham from King’s College London are looking for volunteers to help them trial a different type of intervention aimed at increasing qualit